Did you know that your version of Internet Explorer is out of date?
To get the best possible experience using our website we recommend downloading one of the below web browsers.

Internet Explorer 9, Firefox, Chrome, or Safari.

Treatment Access News

TECHNIVIE has just received a Notice of Compliance from Health Canada

october 21, 2015

ABBVIE’s HCV medication TECHNIVIE has just received a Notice of Compliance from Health Canada. CTAC conducted an informational webinar on this treatment on Sept 21st to complement its Common Drug Review application.

TECHNIVIE is for chronic HCV infection, Genotype 4. It is similar to HOLKIRA PAK, except it does not include Dasabuvir (which is only effective against Genotype 1).

While Genotype 4 accounts for only apprx 2% of the HCV prevalence in Canada (and 6% in the US), it makes up over 15% of all HCV infections globally. 90% of HCV infections in Egypt are Genotype 4 and it is also prevalent in the Middle East and Sub-Saharan Africa. We are seeing increasing rates of Genotype 4 in parts of Europe and Canada due to increased travel and migration from endemic countries.

Learn more about the Common Drug Review process in this brief video.